
    slow accrual, closed by irb
  
['egfr activating mutation', 'recurrent non-small cell lung carcinoma', 'stage iv non-small cell lung cancer']
['chemotherapy', 'targeted molecular therapy', 'tyrosine kinase inhibitor']

        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed incurable non-small cell
             lung cancer that harbors an activating mutation in EGFR, MET, BRAF, V600E, RET, HER2,
             translocation in Alk, or translocation in ROS-1

          -  Patients must be receiving treatment or planning to start treatment with a tyrosine
             kinase inhibitor targeting the activated gene

          -  Patients may not be receiving the treatment targeting the activated gene as part of a
             clinical treatment trial other than the Precision Oncology Trial

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-3

          -  Total bilirubin =< 1.5 X institutional upper limit of normal

          -  Aspartate transaminase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine
             transaminase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X
             institutional upper limit of normal

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control) prior to study entry and for the
             duration of study participation; should a woman become pregnant or suspect she is
             pregnant while participating in this study, she should inform her treating physician
             immediately

          -  Ability to understand and the willingness to sign an Institutional Review Board
             (IRB)-approved informed consent document

        Exclusion Criteria:

          -  Emergent need for palliative radiation

          -  Patients may not be receiving any other investigational agents for the treatment of
             non-small cell lung cancer

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant women are excluded; breastfeeding should be discontinued
      